In the overall Asthma and COPD market, Advair remained the market leader with USD 7,802 million in 2011 and is expected to reach USD xxxx million in 2014. Singulair is the second largest drug in terms of revenue at UD 5479 million in 2011.
Albany, NY -- (SBWIRE) -- 08/17/2016 -- Development of few novel drugs is expected to boost the global asthma and COPD drug market. The report provides a comprehensive study on the global asthma and COPD drug market and assesses the growth of the market during the period between 2010 and 2017. The report also estimates the valuation of the asthma and COPD drug market. Various factors impacting the growth of the global asthma and COPD drug market have been analyzed in the report. The report also studies the impact of Porter's five forces on the overall market.
The report studies the global asthma and COPD drug market on the basis of product type such as anti-inflammatories, bronchodilators, and combination therapies. It forecasts the estimated revenue from each of the product types during the forecast period. Further, the global asthma drug market is analyzed on the basis of branded drugs. The report studies the revenue generated by the drug brands during the period between 2009 and 2011. The cost trends of asthma drugs have been analyzed as well as the emerging treatment options for the disease has been mentioned in the report. The report also analyzes the global COPD market and studies the market share of major COPD drugs.
Complete Report with TOC @ http://www.mrrse.com/asthma-and-copd-market
To analyze the prevailing competitive landscape of the global asthma and COPD drug market, the report profiles some of the key players in the market and provides insightful information about them.
Overview of Global Asthma and COPD Drug Market
The presence of indoor air pollutants and daily exposure to hazardous working environment have increased the number of patients suffering from asthma and COPD. Rise in geriatric population, coupled with increasing population of smokers, also aids the growth of the global asthma and COPD drug market. Better healthcare facility and rise in disposable income are other primary factors fuelling the market growth. However, the patent expiry of many blockbuster brands will create pressure on the global asthma and COPD drug market. Overall high cost of asthma treatment is a challenge for patients, especially for patients without medical insurance.
On the basis of product type, the global asthma and COPD drug market is segmented into anti-inflammatories, bronchodilators, and combination therapies. Bronchodilators' segment is further sub-segmented into long-acting bronchodilators, short-acting bronchodilators, and anticholinergics bronchodilators. Anti-inflammatories' segment is sub-segmented into anti-leukotriene, inhaled corticosteroids, and monoclonal antibodies. The key players are focusing on research and development activities to develop inhaled corticosteroids, beta-agonists, and combination therapies.
Request a Free Sample Copy of the Report @ http://www.mrrse.com/sample/842
Companies mentioned in the research report:
Highlighting the competitive landscape of the global asthma and COPD drug market, the report profiles some of the key players such as GlaxoSmithKline, Merck & Co., Novartis AG, Nycomed, and Boehringer Ingelheim GmbH. The report provides detailed information about the players such as financial overview, geographical presence, net sales, and recent development. The report also discusses the market share of the key players and the competitive strategies implemented by them.
MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.